Amfetamiini (Finnish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Amfetamiini" in Finnish language version.

refsWebsite

Global rank Finnish rank

59nih.gov

4^th place

12^th place

37doi.org

2^nd place

10^th place

36worldcat.org

5^th place

9^th place

4sciencedirect.com

149^th place

237^th place

3web.archive.org

1^st place

3urn.fi

8,035^th place

70^th place

2researchgate.net

120^th place

243^rd place

2finlex.fi

3,070^th place

17^th place

2paihdelinkki.fi

low place

535^th place

2wiley.com

222^nd place

202^nd place

1wada-ama.org

9,542^nd place

low place

1pharmacafennica.fi

low place

904^th place

1kaypahoito.fi

low place

233^rd place

1europa.eu

68^th place

51^st place

1jamanetwork.com

2,650^th place

1,293^rd place

1sagepub.com

731^st place

767^th place

1nature.com

234^th place

201^st place

1aspetjournals.org

6,663^rd place

2,918^th place

1duodecimlehti.fi

low place

109^th place

1yle.fi

380^th place

2^nd place

1julkari.fi

low place

566^th place

1unodc.org

2,494^th place

2,089^th place

aspetjournals.org

jpet.aspetjournals.org

LD Simmler et al: In vitro characterization of psychoactive substances at rat, mouse, and human trace amine-associated receptor 1. Journal of Pharmacology and Experimental Therapeutics, 2016, 357. vsk, nro 1, s. 134–144. PubMed:26791601. doi:10.1124/jpet.115.229765. ISSN 0022-3565. Artikkelin verkkoversio.

doi.org

dx.doi.org

JS Markowitz, KS Patrick: The clinical pharmacokinetics of amphetamines utilized in the treatment of attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 2017, 27. vsk, nro 8, s. 678–689. PubMed:28910145. doi:10.1089/cap.2017.0071. ISSN 1557-8992. Artikkelin verkkoversio.
SL Greene, F Kerr, G Braitberg: Review article: amphetamines and related drugs of abuse. Emergency medicine Australasia, 2008, 20. vsk, nro 5, s. 391–402. PubMed:18973636. doi:10.1111/j.1742-6723.2008.01114.x. ISSN 1742-6723. Artikkelin verkkoversio.
DJ Heal et al: Amphetamine, past and present a pharmacological and clinical perspective. Journal of Psychopharmacology, 2013, 27. vsk, nro 6, s. 479–496. PubMed:23539642. doi:10.1177/0269881113482532. ISSN 0269-8811. Artikkelin verkkoversio.
Amphetamine: a European Union perspective in the global context. Publications Office of the European Union, 2011. ISBN 9789291684915. Teoksen verkkoversio. doi:10.2810/49525.
JCM Brust: Neurological aspects of substance abuse, s. 105–115. 2. painos. Elsevier, 2004. ISBN 9780750673136. doi:10.1016/B978-0-7506-7313-6.50008-8.
A Sinha et al: Amphetamine abuse related acute myocardial infarction. Case Reports in Cardiology, 2016. PubMed:26998366. doi:10.1155/2016/7967851. ISSN 2090-6404. Artikkelin verkkoversio.
PK Gillman: Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. British Journal of Anaesthesia, 2005, 95. vsk, nro 4, s. 434–441. PubMed:16051647. doi:10.1093/bja/aei210. ISSN 0007-0912. Artikkelin verkkoversio.
N Rasmussen: America’s first amphetamine epidemic 1929-1971. American Journal of Public Health, 2008, 98. vsk, nro 6, s. 974–985. PubMed:18445805. doi:10.2105/AJPH.2007.110593. ISSN 0090-0036. Artikkelin verkkoversio.
AC Childress et al: The efficacy and safety of evekeo, racemic amphetamine sulfate, for treatment of attention-deficit/hyperactivity disorder symptoms: a multicenter, dose-optimized, double-blind, randomized, placebo-controlled crossover laboratory classroom study. Journal of Child and Adolescent Psychopharmacology, 2015, 25. vsk, nro 5, s. 402–414. PubMed:25692608. doi:10.1089/cap.2014.0176. ISSN 1044-5463. Artikkelin verkkoversio.
OL Gericke: Suicide by ingestion of amphetamine sulfate. Journal of the American Medical Association, 1945, 128. vsk, nro 15, s. 1098–1099. doi:10.1001/jama.1945.92860320004011b. ISSN 0002-9955. Artikkelin verkkoversio.
EG Zalis et al: Acute lethality of the amphetamines in dogs and its antagonism by curare. Proceedings of the Society for Experimental Biology and Medicine, 1965, 118. vsk, nro 2, s. 557–561. PubMed:14268681. doi:10.3181/00379727-118-29904. ISSN 0037-9727. Artikkelin verkkoversio.
JF Bowyer, JP Hanig: Amphetamine- and methamphetamine-induced hyperthermia: Implications of the effects produced in brain vasculature and peripheral organs to forebrain neurotoxicity. Temperature: Multidisciplinary Biomedical Journal, 2014, 1. vsk, nro 3, s. 172–182. PubMed:27626044. doi:10.4161/23328940.2014.982049. ISSN 2332-8940. Artikkelin verkkoversio.
JG Bramness et al: Amphetamine-induced psychosis - a separate diagnostic entity or primary psychosis triggered in the vulnerable? BMC Psychiatry, 2012, 12. vsk, s. 221–228. PubMed:23216941. doi:10.1186/1471-244X-12-221. ISSN 1471-244X. Artikkelin verkkoversio.
Z Chang et al: Stimulant ADHD medication and risk for substance abuse. Journal of child psychology and psychiatry, and allied disciplines, 2014, 55. vsk, nro 8, s. 878–885. PubMed:25158998. doi:10.1111/jcpp.12164. ISSN 0021-9630. Artikkelin verkkoversio.
KM Harlé, AJ Yu, MP Paulus: Bayesian computational markers of relapse in methamphetamine dependence. NeuroImage: Clinical, 2019, 22. vsk. PubMed:30928810. doi:10.1016/j.nicl.2019.101794. ISSN 2213-1582. Artikkelin verkkoversio.
M Brecht, D Herbeck: Time to relapse following treatment for methamphetamine use: a long-term perspective on patterns and predictors. Drug and alcohol dependence, 2014, 139. vsk, s. 18–25. PubMed:24685563. doi:10.1016/j.drugalcdep.2014.02.702. ISSN 0376-8716. Artikkelin verkkoversio.
H Tan et al: History of alcohol and opioid use impacts on the long-term recovery trajectories of methamphetamine-dependent patients. Frontiers in Psychiatry, 2019, 10. vsk. PubMed:31231256. doi:10.3389/fpsyt.2019.00398. ISSN 1664-0640. Artikkelin verkkoversio.
A Sinha et al: Adult ADHD medications and their cardiovascular implications. Case Reports in Cardiology, 2016. PubMed:27579185. doi:10.1155/2016/2343691. ISSN 2090-6404. Artikkelin verkkoversio.
TM Furlong et al: Methamphetamine, d-amphetamine and p-chloroamphetamine induced neurotoxicity differentially effect impulsive responding on the stop-signal task in rats. Neurotoxicity research, 2016, 29. vsk, nro 4, s. 569–582. PubMed:26846719. doi:10.1007/s12640-016-9605-9. ISSN 1029-8428. Artikkelin verkkoversio.
C Ferreira et al: Neuroprotection or neurotoxicity of illicit drugs on Parkinson’s disease. Life, 2020, 10. vsk, nro 6. PubMed:32545328. doi:10.3390/life10060086. ISSN 2075-1729. Artikkelin verkkoversio.
JL Oei et al: Amphetamines, the pregnant woman and her children: a review. Journal of Perinatology, 2012, 32. vsk, nro 10, s. 737–747. PubMed:22652562. doi:10.1038/jp.2012.59. ISSN 1476-5543. Artikkelin verkkoversio.
I Peña, R Gevorkiana, W Shi: Psychostimulants affect dopamine transmission through both dopamine transporter-dependent and independent mechanisms. European journal of pharmacology, 2015, 764. vsk, s. 562–570. PubMed:26209364. doi:10.1016/j.ejphar.2015.07.044. ISSN 0014-2999. Artikkelin verkkoversio.
K Stemmer et al: CNS-targeting pharmacological interventions for the metabolic syndrome. The Journal of Clinical Investigation, 2019, 129. vsk, nro 10, s. 4058–4071. PubMed:31380808. doi:10.1172/JCI129195. ISSN 0021-9738. Artikkelin verkkoversio.
F Ferrucci et al: The effects of amphetamine and methamphetamine on the release of norepinephrine, dopamine and acetylcholine from the brainstem reticular formation. Frontiers in Neuroanatomy, 2019, 13. vsk. PubMed:31133823. doi:10.3389/fnana.2019.00048. ISSN 1662-5129. Artikkelin verkkoversio.
DD Han, HH Gu: Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacology, 2006, 6. vsk, s. 6–13. PubMed:16515684. doi:10.1186/1471-2210-6-6. ISSN 1471-2210. Artikkelin verkkoversio.
PS Hasenhuetl et al: A kinetic account for amphetamine-induced monoamine release. The Journal of General Physiology, 2018, 150. vsk, nro 3, s. 431–451. PubMed:29439119. doi:10.1085/jgp.201711915. ISSN 0022-1295. Artikkelin verkkoversio.
FP Mayer et al: An unsuspected role for organic cation transporter 3 in the actions of amphetamine. Neuropsychopharmacology, 2018, 43. vsk, nro 12, s. 2408–2417. PubMed:29773909. doi:10.1038/s41386-018-0053-5. ISSN 0893-133X. Artikkelin verkkoversio.
Z Freyberg et al: Mechanisms of amphetamine action illuminated through optical monitoring of dopamine synaptic vesicles in Drosophila brain. Nature Communications, 2016, 7. vsk, nro 10652. PubMed:26879809. doi:10.1038/ncomms10652. ISSN 2041-1723. Artikkelin verkkoversio.
LD Simmler et al: In vitro characterization of psychoactive substances at rat, mouse, and human trace amine-associated receptor 1. Journal of Pharmacology and Experimental Therapeutics, 2016, 357. vsk, nro 1, s. 134–144. PubMed:26791601. doi:10.1124/jpet.115.229765. ISSN 0022-3565. Artikkelin verkkoversio.
J Liu, R Wu, J Li: TAAR1 and psychostimulant addiction. Cellular and Molecular Neurobiology, 2020, 40. vsk, nro 2, s. 229–238. PubMed:31974906. doi:10.1007/s10571-020-00792-8. ISSN 1573-6830. Artikkelin verkkoversio.
IH Ulus, TJ Maher, RJ Wurtman: Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors. Biochemical Pharmacology, 2000, 59. vsk, nro 12, s. 1611–1621. PubMed:10799660. doi:10.1016/s0006-2952(00)00306-3. ISSN 0006-2952. Artikkelin verkkoversio.
JB Robinson: Stereoselectivity and isoenzyme selectivity of monoamine oxidase inhibitors. Enantiomers of amphetamine, N-methylamphetamine and deprenyl. Biochemical Pharmacology, 1985, 34. vsk, nro 23, s. 4105–4108. PubMed:3933519. doi:10.1016/0006-2952(85)90201-1. Artikkelin verkkoversio.
J Kitanaka, N Kitanaka, M Takemura: Modification of monoaminergic activity by MAO inhibitors influences methamphetamine actions. Drug Target Insights, 2006, 1. vsk, s. 19–28. PubMed:21901055. doi:10.1177/117739280600100001. ISSN 1177-3928. Artikkelin verkkoversio.
SE Hadland, S Levy: Objective testing - urine and other drug tests. Child and adolescent psychiatric clinics of North America, 2016, 25. vsk, nro 3, s. 549–565. PubMed:27338974. doi:10.1016/j.chc.2016.02.005. ISSN 1056-4993. Artikkelin verkkoversio.
L Edeleano: Ueber einige derivate der phenylmethacrylsäure und der phenylisobuttersäure. Berichte der deutschen chemischen Gesellschaft, 1887, 20. vsk, nro 1, s. 616–622. doi:10.1002/cber.188702001142. ISSN 1099-0682. Artikkelin verkkoversio.
BA Clement eta l: Toxic amines and alkaloids from Acacia berlandieri. Phytochemistry, 1997, 46. vsk, nro 2, s. 249–254. doi:10.1016/S0031-9422(97)00240-9. ISSN 0031-9422. Artikkelin verkkoversio.
SM Berman et al: Potential adverse effects of amphetamine treatment on brain and behavior: a review. Molecular Psychiatry, 2009, nro 2, s. 123–142. PubMed:18698321. doi:10.1038/mp.2008.90. ISSN 1476-5578. Artikkelin verkkoversio.

duodecimlehti.fi

S Rönkä: Amfetamiinien ja opioidien ongelmakäytön yleisyys Suomessa vuonna 2017. Duodecim, 2020, 136. vsk, nro 8, s. 927–935. Artikkelin verkkoversio.

europa.eu

emcdda.europa.eu

Amphetamine: a European Union perspective in the global context. Publications Office of the European Union, 2011. ISBN 9789291684915. Teoksen verkkoversio. doi:10.2810/49525.

finlex.fi

Valtioneuvoston asetus huumausaineina… 543/2008 finlex.fi. Viitattu 5.12.2020.
Korkeimman oikeuden ennakkopäätökset: KKO:1998:162 finlex.fi. Viitattu 5.12.2020.

jamanetwork.com

OL Gericke: Suicide by ingestion of amphetamine sulfate. Journal of the American Medical Association, 1945, 128. vsk, nro 15, s. 1098–1099. doi:10.1001/jama.1945.92860320004011b. ISSN 0002-9955. Artikkelin verkkoversio.

julkari.fi

S Rönkä, A Virtanen: Huumetilanne Suomessa 2009, s. 129–130. Terveyden ja Hyvinvoinnin Laitos, 2009. ISBN 9789522451903. Teoksen verkkoversio.

kaypahoito.fi

ADHD (aktiivisuuden ja tarkkaavuuden häiriö) kaypahoito.fi. Viitattu 5.12.2020.

nature.com

JL Oei et al: Amphetamines, the pregnant woman and her children: a review. Journal of Perinatology, 2012, 32. vsk, nro 10, s. 737–747. PubMed:22652562. doi:10.1038/jp.2012.59. ISSN 1476-5543. Artikkelin verkkoversio.

nih.gov

pubmed.ncbi.nlm.nih.gov

JS Markowitz, KS Patrick: The clinical pharmacokinetics of amphetamines utilized in the treatment of attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 2017, 27. vsk, nro 8, s. 678–689. PubMed:28910145. doi:10.1089/cap.2017.0071. ISSN 1557-8992. Artikkelin verkkoversio.
SL Greene, F Kerr, G Braitberg: Review article: amphetamines and related drugs of abuse. Emergency medicine Australasia, 2008, 20. vsk, nro 5, s. 391–402. PubMed:18973636. doi:10.1111/j.1742-6723.2008.01114.x. ISSN 1742-6723. Artikkelin verkkoversio.
DJ Heal et al: Amphetamine, past and present a pharmacological and clinical perspective. Journal of Psychopharmacology, 2013, 27. vsk, nro 6, s. 479–496. PubMed:23539642. doi:10.1177/0269881113482532. ISSN 0269-8811. Artikkelin verkkoversio.
A Sinha et al: Amphetamine abuse related acute myocardial infarction. Case Reports in Cardiology, 2016. PubMed:26998366. doi:10.1155/2016/7967851. ISSN 2090-6404. Artikkelin verkkoversio.
PK Gillman: Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. British Journal of Anaesthesia, 2005, 95. vsk, nro 4, s. 434–441. PubMed:16051647. doi:10.1093/bja/aei210. ISSN 0007-0912. Artikkelin verkkoversio.
N Rasmussen: America’s first amphetamine epidemic 1929-1971. American Journal of Public Health, 2008, 98. vsk, nro 6, s. 974–985. PubMed:18445805. doi:10.2105/AJPH.2007.110593. ISSN 0090-0036. Artikkelin verkkoversio.
AC Childress et al: The efficacy and safety of evekeo, racemic amphetamine sulfate, for treatment of attention-deficit/hyperactivity disorder symptoms: a multicenter, dose-optimized, double-blind, randomized, placebo-controlled crossover laboratory classroom study. Journal of Child and Adolescent Psychopharmacology, 2015, 25. vsk, nro 5, s. 402–414. PubMed:25692608. doi:10.1089/cap.2014.0176. ISSN 1044-5463. Artikkelin verkkoversio.
BM Askew: Hyperpyrexia as a contributory factor in the toxicity of amphetamine to aggregated mice. British Journal of Pharmacology and Chemotherapy, 1962, 19. vsk, nro 2, s. 245–257. PubMed:13965240. ISSN 0366-0826. Artikkelin verkkoversio.
EG Zalis et al: Acute lethality of the amphetamines in dogs and its antagonism by curare. Proceedings of the Society for Experimental Biology and Medicine, 1965, 118. vsk, nro 2, s. 557–561. PubMed:14268681. doi:10.3181/00379727-118-29904. ISSN 0037-9727. Artikkelin verkkoversio.
JF Bowyer, JP Hanig: Amphetamine- and methamphetamine-induced hyperthermia: Implications of the effects produced in brain vasculature and peripheral organs to forebrain neurotoxicity. Temperature: Multidisciplinary Biomedical Journal, 2014, 1. vsk, nro 3, s. 172–182. PubMed:27626044. doi:10.4161/23328940.2014.982049. ISSN 2332-8940. Artikkelin verkkoversio.
JG Bramness et al: Amphetamine-induced psychosis - a separate diagnostic entity or primary psychosis triggered in the vulnerable? BMC Psychiatry, 2012, 12. vsk, s. 221–228. PubMed:23216941. doi:10.1186/1471-244X-12-221. ISSN 1471-244X. Artikkelin verkkoversio.
Z Chang et al: Stimulant ADHD medication and risk for substance abuse. Journal of child psychology and psychiatry, and allied disciplines, 2014, 55. vsk, nro 8, s. 878–885. PubMed:25158998. doi:10.1111/jcpp.12164. ISSN 0021-9630. Artikkelin verkkoversio.
KM Harlé, AJ Yu, MP Paulus: Bayesian computational markers of relapse in methamphetamine dependence. NeuroImage: Clinical, 2019, 22. vsk. PubMed:30928810. doi:10.1016/j.nicl.2019.101794. ISSN 2213-1582. Artikkelin verkkoversio.
M Brecht, D Herbeck: Time to relapse following treatment for methamphetamine use: a long-term perspective on patterns and predictors. Drug and alcohol dependence, 2014, 139. vsk, s. 18–25. PubMed:24685563. doi:10.1016/j.drugalcdep.2014.02.702. ISSN 0376-8716. Artikkelin verkkoversio.
H Tan et al: History of alcohol and opioid use impacts on the long-term recovery trajectories of methamphetamine-dependent patients. Frontiers in Psychiatry, 2019, 10. vsk. PubMed:31231256. doi:10.3389/fpsyt.2019.00398. ISSN 1664-0640. Artikkelin verkkoversio.
A Sinha et al: Adult ADHD medications and their cardiovascular implications. Case Reports in Cardiology, 2016. PubMed:27579185. doi:10.1155/2016/2343691. ISSN 2090-6404. Artikkelin verkkoversio.
TM Furlong et al: Methamphetamine, d-amphetamine and p-chloroamphetamine induced neurotoxicity differentially effect impulsive responding on the stop-signal task in rats. Neurotoxicity research, 2016, 29. vsk, nro 4, s. 569–582. PubMed:26846719. doi:10.1007/s12640-016-9605-9. ISSN 1029-8428. Artikkelin verkkoversio.
C Ferreira et al: Neuroprotection or neurotoxicity of illicit drugs on Parkinson’s disease. Life, 2020, 10. vsk, nro 6. PubMed:32545328. doi:10.3390/life10060086. ISSN 2075-1729. Artikkelin verkkoversio.
JL Oei et al: Amphetamines, the pregnant woman and her children: a review. Journal of Perinatology, 2012, 32. vsk, nro 10, s. 737–747. PubMed:22652562. doi:10.1038/jp.2012.59. ISSN 1476-5543. Artikkelin verkkoversio.
I Peña, R Gevorkiana, W Shi: Psychostimulants affect dopamine transmission through both dopamine transporter-dependent and independent mechanisms. European journal of pharmacology, 2015, 764. vsk, s. 562–570. PubMed:26209364. doi:10.1016/j.ejphar.2015.07.044. ISSN 0014-2999. Artikkelin verkkoversio.
K Stemmer et al: CNS-targeting pharmacological interventions for the metabolic syndrome. The Journal of Clinical Investigation, 2019, 129. vsk, nro 10, s. 4058–4071. PubMed:31380808. doi:10.1172/JCI129195. ISSN 0021-9738. Artikkelin verkkoversio.
F Ferrucci et al: The effects of amphetamine and methamphetamine on the release of norepinephrine, dopamine and acetylcholine from the brainstem reticular formation. Frontiers in Neuroanatomy, 2019, 13. vsk. PubMed:31133823. doi:10.3389/fnana.2019.00048. ISSN 1662-5129. Artikkelin verkkoversio.
DD Han, HH Gu: Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacology, 2006, 6. vsk, s. 6–13. PubMed:16515684. doi:10.1186/1471-2210-6-6. ISSN 1471-2210. Artikkelin verkkoversio.
PS Hasenhuetl et al: A kinetic account for amphetamine-induced monoamine release. The Journal of General Physiology, 2018, 150. vsk, nro 3, s. 431–451. PubMed:29439119. doi:10.1085/jgp.201711915. ISSN 0022-1295. Artikkelin verkkoversio.
FP Mayer et al: An unsuspected role for organic cation transporter 3 in the actions of amphetamine. Neuropsychopharmacology, 2018, 43. vsk, nro 12, s. 2408–2417. PubMed:29773909. doi:10.1038/s41386-018-0053-5. ISSN 0893-133X. Artikkelin verkkoversio.
Z Freyberg et al: Mechanisms of amphetamine action illuminated through optical monitoring of dopamine synaptic vesicles in Drosophila brain. Nature Communications, 2016, 7. vsk, nro 10652. PubMed:26879809. doi:10.1038/ncomms10652. ISSN 2041-1723. Artikkelin verkkoversio.
LD Simmler et al: In vitro characterization of psychoactive substances at rat, mouse, and human trace amine-associated receptor 1. Journal of Pharmacology and Experimental Therapeutics, 2016, 357. vsk, nro 1, s. 134–144. PubMed:26791601. doi:10.1124/jpet.115.229765. ISSN 0022-3565. Artikkelin verkkoversio.
J Liu, R Wu, J Li: TAAR1 and psychostimulant addiction. Cellular and Molecular Neurobiology, 2020, 40. vsk, nro 2, s. 229–238. PubMed:31974906. doi:10.1007/s10571-020-00792-8. ISSN 1573-6830. Artikkelin verkkoversio.
IH Ulus, TJ Maher, RJ Wurtman: Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors. Biochemical Pharmacology, 2000, 59. vsk, nro 12, s. 1611–1621. PubMed:10799660. doi:10.1016/s0006-2952(00)00306-3. ISSN 0006-2952. Artikkelin verkkoversio.
JB Robinson: Stereoselectivity and isoenzyme selectivity of monoamine oxidase inhibitors. Enantiomers of amphetamine, N-methylamphetamine and deprenyl. Biochemical Pharmacology, 1985, 34. vsk, nro 23, s. 4105–4108. PubMed:3933519. doi:10.1016/0006-2952(85)90201-1. Artikkelin verkkoversio.
J Kitanaka, N Kitanaka, M Takemura: Modification of monoaminergic activity by MAO inhibitors influences methamphetamine actions. Drug Target Insights, 2006, 1. vsk, s. 19–28. PubMed:21901055. doi:10.1177/117739280600100001. ISSN 1177-3928. Artikkelin verkkoversio.
SE Hadland, S Levy: Objective testing - urine and other drug tests. Child and adolescent psychiatric clinics of North America, 2016, 25. vsk, nro 3, s. 549–565. PubMed:27338974. doi:10.1016/j.chc.2016.02.005. ISSN 1056-4993. Artikkelin verkkoversio.
SM Berman et al: Potential adverse effects of amphetamine treatment on brain and behavior: a review. Molecular Psychiatry, 2009, nro 2, s. 123–142. PubMed:18698321. doi:10.1038/mp.2008.90. ISSN 1476-5578. Artikkelin verkkoversio.
MP Strohl: Bradley’s benzedrine studies on children with behavioral disorders. The Yale Journal of Biology and Medicine, 2011, 84. vsk, nro 1, s. 27–33. PubMed:21451781. ISSN 0044-0086. Artikkelin verkkoversio.

ncbi.nlm.nih.gov

DJ Heal et al: Amphetamine, past and present a pharmacological and clinical perspective. Journal of Psychopharmacology, 2013, 27. vsk, nro 6, s. 479–496. PubMed:23539642. doi:10.1177/0269881113482532. ISSN 0269-8811. Artikkelin verkkoversio.
A Sinha et al: Amphetamine abuse related acute myocardial infarction. Case Reports in Cardiology, 2016. PubMed:26998366. doi:10.1155/2016/7967851. ISSN 2090-6404. Artikkelin verkkoversio.
N Rasmussen: America’s first amphetamine epidemic 1929-1971. American Journal of Public Health, 2008, 98. vsk, nro 6, s. 974–985. PubMed:18445805. doi:10.2105/AJPH.2007.110593. ISSN 0090-0036. Artikkelin verkkoversio.
AC Childress et al: The efficacy and safety of evekeo, racemic amphetamine sulfate, for treatment of attention-deficit/hyperactivity disorder symptoms: a multicenter, dose-optimized, double-blind, randomized, placebo-controlled crossover laboratory classroom study. Journal of Child and Adolescent Psychopharmacology, 2015, 25. vsk, nro 5, s. 402–414. PubMed:25692608. doi:10.1089/cap.2014.0176. ISSN 1044-5463. Artikkelin verkkoversio.
BM Askew: Hyperpyrexia as a contributory factor in the toxicity of amphetamine to aggregated mice. British Journal of Pharmacology and Chemotherapy, 1962, 19. vsk, nro 2, s. 245–257. PubMed:13965240. ISSN 0366-0826. Artikkelin verkkoversio.
JF Bowyer, JP Hanig: Amphetamine- and methamphetamine-induced hyperthermia: Implications of the effects produced in brain vasculature and peripheral organs to forebrain neurotoxicity. Temperature: Multidisciplinary Biomedical Journal, 2014, 1. vsk, nro 3, s. 172–182. PubMed:27626044. doi:10.4161/23328940.2014.982049. ISSN 2332-8940. Artikkelin verkkoversio.
JG Bramness et al: Amphetamine-induced psychosis - a separate diagnostic entity or primary psychosis triggered in the vulnerable? BMC Psychiatry, 2012, 12. vsk, s. 221–228. PubMed:23216941. doi:10.1186/1471-244X-12-221. ISSN 1471-244X. Artikkelin verkkoversio.
Z Chang et al: Stimulant ADHD medication and risk for substance abuse. Journal of child psychology and psychiatry, and allied disciplines, 2014, 55. vsk, nro 8, s. 878–885. PubMed:25158998. doi:10.1111/jcpp.12164. ISSN 0021-9630. Artikkelin verkkoversio.
KM Harlé, AJ Yu, MP Paulus: Bayesian computational markers of relapse in methamphetamine dependence. NeuroImage: Clinical, 2019, 22. vsk. PubMed:30928810. doi:10.1016/j.nicl.2019.101794. ISSN 2213-1582. Artikkelin verkkoversio.
M Brecht, D Herbeck: Time to relapse following treatment for methamphetamine use: a long-term perspective on patterns and predictors. Drug and alcohol dependence, 2014, 139. vsk, s. 18–25. PubMed:24685563. doi:10.1016/j.drugalcdep.2014.02.702. ISSN 0376-8716. Artikkelin verkkoversio.
H Tan et al: History of alcohol and opioid use impacts on the long-term recovery trajectories of methamphetamine-dependent patients. Frontiers in Psychiatry, 2019, 10. vsk. PubMed:31231256. doi:10.3389/fpsyt.2019.00398. ISSN 1664-0640. Artikkelin verkkoversio.
A Sinha et al: Adult ADHD medications and their cardiovascular implications. Case Reports in Cardiology, 2016. PubMed:27579185. doi:10.1155/2016/2343691. ISSN 2090-6404. Artikkelin verkkoversio.
TM Furlong et al: Methamphetamine, d-amphetamine and p-chloroamphetamine induced neurotoxicity differentially effect impulsive responding on the stop-signal task in rats. Neurotoxicity research, 2016, 29. vsk, nro 4, s. 569–582. PubMed:26846719. doi:10.1007/s12640-016-9605-9. ISSN 1029-8428. Artikkelin verkkoversio.
C Ferreira et al: Neuroprotection or neurotoxicity of illicit drugs on Parkinson’s disease. Life, 2020, 10. vsk, nro 6. PubMed:32545328. doi:10.3390/life10060086. ISSN 2075-1729. Artikkelin verkkoversio.
I Peña, R Gevorkiana, W Shi: Psychostimulants affect dopamine transmission through both dopamine transporter-dependent and independent mechanisms. European journal of pharmacology, 2015, 764. vsk, s. 562–570. PubMed:26209364. doi:10.1016/j.ejphar.2015.07.044. ISSN 0014-2999. Artikkelin verkkoversio.
K Stemmer et al: CNS-targeting pharmacological interventions for the metabolic syndrome. The Journal of Clinical Investigation, 2019, 129. vsk, nro 10, s. 4058–4071. PubMed:31380808. doi:10.1172/JCI129195. ISSN 0021-9738. Artikkelin verkkoversio.
F Ferrucci et al: The effects of amphetamine and methamphetamine on the release of norepinephrine, dopamine and acetylcholine from the brainstem reticular formation. Frontiers in Neuroanatomy, 2019, 13. vsk. PubMed:31133823. doi:10.3389/fnana.2019.00048. ISSN 1662-5129. Artikkelin verkkoversio.
DD Han, HH Gu: Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacology, 2006, 6. vsk, s. 6–13. PubMed:16515684. doi:10.1186/1471-2210-6-6. ISSN 1471-2210. Artikkelin verkkoversio.
PS Hasenhuetl et al: A kinetic account for amphetamine-induced monoamine release. The Journal of General Physiology, 2018, 150. vsk, nro 3, s. 431–451. PubMed:29439119. doi:10.1085/jgp.201711915. ISSN 0022-1295. Artikkelin verkkoversio.
FP Mayer et al: An unsuspected role for organic cation transporter 3 in the actions of amphetamine. Neuropsychopharmacology, 2018, 43. vsk, nro 12, s. 2408–2417. PubMed:29773909. doi:10.1038/s41386-018-0053-5. ISSN 0893-133X. Artikkelin verkkoversio.
Z Freyberg et al: Mechanisms of amphetamine action illuminated through optical monitoring of dopamine synaptic vesicles in Drosophila brain. Nature Communications, 2016, 7. vsk, nro 10652. PubMed:26879809. doi:10.1038/ncomms10652. ISSN 2041-1723. Artikkelin verkkoversio.
J Kitanaka, N Kitanaka, M Takemura: Modification of monoaminergic activity by MAO inhibitors influences methamphetamine actions. Drug Target Insights, 2006, 1. vsk, s. 19–28. PubMed:21901055. doi:10.1177/117739280600100001. ISSN 1177-3928. Artikkelin verkkoversio.
SE Hadland, S Levy: Objective testing - urine and other drug tests. Child and adolescent psychiatric clinics of North America, 2016, 25. vsk, nro 3, s. 549–565. PubMed:27338974. doi:10.1016/j.chc.2016.02.005. ISSN 1056-4993. Artikkelin verkkoversio.
SM Berman et al: Potential adverse effects of amphetamine treatment on brain and behavior: a review. Molecular Psychiatry, 2009, nro 2, s. 123–142. PubMed:18698321. doi:10.1038/mp.2008.90. ISSN 1476-5578. Artikkelin verkkoversio.
MP Strohl: Bradley’s benzedrine studies on children with behavioral disorders. The Yale Journal of Biology and Medicine, 2011, 84. vsk, nro 1, s. 27–33. PubMed:21451781. ISSN 0044-0086. Artikkelin verkkoversio.

paihdelinkki.fi

Amfetamiini paihdelinkki.fi. 22.4.2014. Viitattu 5.12.2020.
Amfetamiini, metamfetamiini sekä muut piristeet paihdelinkki.fi. 13.6.2014. Viitattu 5.12.2020.

pharmacafennica.fi

Määritä nimeke! Lääketietokeskus. Viitattu 27.3.2023.

researchgate.net

JS Markowitz, KS Patrick: The clinical pharmacokinetics of amphetamines utilized in the treatment of attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 2017, 27. vsk, nro 8, s. 678–689. PubMed:28910145. doi:10.1089/cap.2017.0071. ISSN 1557-8992. Artikkelin verkkoversio.
J Liu, R Wu, J Li: TAAR1 and psychostimulant addiction. Cellular and Molecular Neurobiology, 2020, 40. vsk, nro 2, s. 229–238. PubMed:31974906. doi:10.1007/s10571-020-00792-8. ISSN 1573-6830. Artikkelin verkkoversio.

sagepub.com

journals.sagepub.com

EG Zalis et al: Acute lethality of the amphetamines in dogs and its antagonism by curare. Proceedings of the Society for Experimental Biology and Medicine, 1965, 118. vsk, nro 2, s. 557–561. PubMed:14268681. doi:10.3181/00379727-118-29904. ISSN 0037-9727. Artikkelin verkkoversio.

sciencedirect.com

PK Gillman: Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. British Journal of Anaesthesia, 2005, 95. vsk, nro 4, s. 434–441. PubMed:16051647. doi:10.1093/bja/aei210. ISSN 0007-0912. Artikkelin verkkoversio.
IH Ulus, TJ Maher, RJ Wurtman: Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors. Biochemical Pharmacology, 2000, 59. vsk, nro 12, s. 1611–1621. PubMed:10799660. doi:10.1016/s0006-2952(00)00306-3. ISSN 0006-2952. Artikkelin verkkoversio.
JB Robinson: Stereoselectivity and isoenzyme selectivity of monoamine oxidase inhibitors. Enantiomers of amphetamine, N-methylamphetamine and deprenyl. Biochemical Pharmacology, 1985, 34. vsk, nro 23, s. 4105–4108. PubMed:3933519. doi:10.1016/0006-2952(85)90201-1. Artikkelin verkkoversio.
BA Clement eta l: Toxic amines and alkaloids from Acacia berlandieri. Phytochemistry, 1997, 46. vsk, nro 2, s. 249–254. doi:10.1016/S0031-9422(97)00240-9. ISSN 0031-9422. Artikkelin verkkoversio.

unodc.org

Sweden’s successful drug policy: a review of the evidence 2007. United Nations. Arkistoitu 17.5.2020.

urn.fi

P Partanen: Amfetamiinien ja opiaattien ongelmakäytön yleisyys Suomessa 2005. Yhteiskuntapolitiikka, 2007, 72. vsk, nro 5, s. 553–561. Artikkelin verkkoversio.
J Ollgren et al: Amfetamiinien ja opioidien ongelmakäytön yleisyys Suomessa 2012. Yhteiskuntapolitiikka, 2014, 74. vsk, nro 5, s. 498–508. Artikkelin verkkoversio.
K Karjalainen, N Pekkanen, P Hakkarainen: Suomalaisten huumeiden käyttö ja huumeasenteet: Huumeaiheiset väestökyselyt Suomessa 1992-2018, s. 57–58. THL, 2020. ISBN 9789523434417. Teoksen verkkoversio.

wada-ama.org

Prohibited list, january 2020 WADA. Viitattu 8.12.2020.

web.archive.org

A Allen, R Ely: Review: synthetic methods for amphetamine web.archive.org. Viitattu 4.12.2020.
kultti.net : SisutablettejaArkistoitu kopio web.archive.org. Arkistoitu 27.3.2007. Viitattu 30.9.2021.
Sweden’s successful drug policy: a review of the evidence 2007. United Nations. Arkistoitu 17.5.2020.

wiley.com

onlinelibrary.wiley.com

SL Greene, F Kerr, G Braitberg: Review article: amphetamines and related drugs of abuse. Emergency medicine Australasia, 2008, 20. vsk, nro 5, s. 391–402. PubMed:18973636. doi:10.1111/j.1742-6723.2008.01114.x. ISSN 1742-6723. Artikkelin verkkoversio.

chemistry-europe.onlinelibrary.wiley.com

L Edeleano: Ueber einige derivate der phenylmethacrylsäure und der phenylisobuttersäure. Berichte der deutschen chemischen Gesellschaft, 1887, 20. vsk, nro 1, s. 616–622. doi:10.1002/cber.188702001142. ISSN 1099-0682. Artikkelin verkkoversio.

worldcat.org

JS Markowitz, KS Patrick: The clinical pharmacokinetics of amphetamines utilized in the treatment of attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 2017, 27. vsk, nro 8, s. 678–689. PubMed:28910145. doi:10.1089/cap.2017.0071. ISSN 1557-8992. Artikkelin verkkoversio.
SL Greene, F Kerr, G Braitberg: Review article: amphetamines and related drugs of abuse. Emergency medicine Australasia, 2008, 20. vsk, nro 5, s. 391–402. PubMed:18973636. doi:10.1111/j.1742-6723.2008.01114.x. ISSN 1742-6723. Artikkelin verkkoversio.
DJ Heal et al: Amphetamine, past and present a pharmacological and clinical perspective. Journal of Psychopharmacology, 2013, 27. vsk, nro 6, s. 479–496. PubMed:23539642. doi:10.1177/0269881113482532. ISSN 0269-8811. Artikkelin verkkoversio.
A Sinha et al: Amphetamine abuse related acute myocardial infarction. Case Reports in Cardiology, 2016. PubMed:26998366. doi:10.1155/2016/7967851. ISSN 2090-6404. Artikkelin verkkoversio.
PK Gillman: Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. British Journal of Anaesthesia, 2005, 95. vsk, nro 4, s. 434–441. PubMed:16051647. doi:10.1093/bja/aei210. ISSN 0007-0912. Artikkelin verkkoversio.
N Rasmussen: America’s first amphetamine epidemic 1929-1971. American Journal of Public Health, 2008, 98. vsk, nro 6, s. 974–985. PubMed:18445805. doi:10.2105/AJPH.2007.110593. ISSN 0090-0036. Artikkelin verkkoversio.
AC Childress et al: The efficacy and safety of evekeo, racemic amphetamine sulfate, for treatment of attention-deficit/hyperactivity disorder symptoms: a multicenter, dose-optimized, double-blind, randomized, placebo-controlled crossover laboratory classroom study. Journal of Child and Adolescent Psychopharmacology, 2015, 25. vsk, nro 5, s. 402–414. PubMed:25692608. doi:10.1089/cap.2014.0176. ISSN 1044-5463. Artikkelin verkkoversio.
OL Gericke: Suicide by ingestion of amphetamine sulfate. Journal of the American Medical Association, 1945, 128. vsk, nro 15, s. 1098–1099. doi:10.1001/jama.1945.92860320004011b. ISSN 0002-9955. Artikkelin verkkoversio.
BM Askew: Hyperpyrexia as a contributory factor in the toxicity of amphetamine to aggregated mice. British Journal of Pharmacology and Chemotherapy, 1962, 19. vsk, nro 2, s. 245–257. PubMed:13965240. ISSN 0366-0826. Artikkelin verkkoversio.
EG Zalis et al: Acute lethality of the amphetamines in dogs and its antagonism by curare. Proceedings of the Society for Experimental Biology and Medicine, 1965, 118. vsk, nro 2, s. 557–561. PubMed:14268681. doi:10.3181/00379727-118-29904. ISSN 0037-9727. Artikkelin verkkoversio.
JF Bowyer, JP Hanig: Amphetamine- and methamphetamine-induced hyperthermia: Implications of the effects produced in brain vasculature and peripheral organs to forebrain neurotoxicity. Temperature: Multidisciplinary Biomedical Journal, 2014, 1. vsk, nro 3, s. 172–182. PubMed:27626044. doi:10.4161/23328940.2014.982049. ISSN 2332-8940. Artikkelin verkkoversio.
JG Bramness et al: Amphetamine-induced psychosis - a separate diagnostic entity or primary psychosis triggered in the vulnerable? BMC Psychiatry, 2012, 12. vsk, s. 221–228. PubMed:23216941. doi:10.1186/1471-244X-12-221. ISSN 1471-244X. Artikkelin verkkoversio.
Z Chang et al: Stimulant ADHD medication and risk for substance abuse. Journal of child psychology and psychiatry, and allied disciplines, 2014, 55. vsk, nro 8, s. 878–885. PubMed:25158998. doi:10.1111/jcpp.12164. ISSN 0021-9630. Artikkelin verkkoversio.
KM Harlé, AJ Yu, MP Paulus: Bayesian computational markers of relapse in methamphetamine dependence. NeuroImage: Clinical, 2019, 22. vsk. PubMed:30928810. doi:10.1016/j.nicl.2019.101794. ISSN 2213-1582. Artikkelin verkkoversio.
M Brecht, D Herbeck: Time to relapse following treatment for methamphetamine use: a long-term perspective on patterns and predictors. Drug and alcohol dependence, 2014, 139. vsk, s. 18–25. PubMed:24685563. doi:10.1016/j.drugalcdep.2014.02.702. ISSN 0376-8716. Artikkelin verkkoversio.
H Tan et al: History of alcohol and opioid use impacts on the long-term recovery trajectories of methamphetamine-dependent patients. Frontiers in Psychiatry, 2019, 10. vsk. PubMed:31231256. doi:10.3389/fpsyt.2019.00398. ISSN 1664-0640. Artikkelin verkkoversio.
A Sinha et al: Adult ADHD medications and their cardiovascular implications. Case Reports in Cardiology, 2016. PubMed:27579185. doi:10.1155/2016/2343691. ISSN 2090-6404. Artikkelin verkkoversio.
TM Furlong et al: Methamphetamine, d-amphetamine and p-chloroamphetamine induced neurotoxicity differentially effect impulsive responding on the stop-signal task in rats. Neurotoxicity research, 2016, 29. vsk, nro 4, s. 569–582. PubMed:26846719. doi:10.1007/s12640-016-9605-9. ISSN 1029-8428. Artikkelin verkkoversio.
C Ferreira et al: Neuroprotection or neurotoxicity of illicit drugs on Parkinson’s disease. Life, 2020, 10. vsk, nro 6. PubMed:32545328. doi:10.3390/life10060086. ISSN 2075-1729. Artikkelin verkkoversio.
JL Oei et al: Amphetamines, the pregnant woman and her children: a review. Journal of Perinatology, 2012, 32. vsk, nro 10, s. 737–747. PubMed:22652562. doi:10.1038/jp.2012.59. ISSN 1476-5543. Artikkelin verkkoversio.
I Peña, R Gevorkiana, W Shi: Psychostimulants affect dopamine transmission through both dopamine transporter-dependent and independent mechanisms. European journal of pharmacology, 2015, 764. vsk, s. 562–570. PubMed:26209364. doi:10.1016/j.ejphar.2015.07.044. ISSN 0014-2999. Artikkelin verkkoversio.
K Stemmer et al: CNS-targeting pharmacological interventions for the metabolic syndrome. The Journal of Clinical Investigation, 2019, 129. vsk, nro 10, s. 4058–4071. PubMed:31380808. doi:10.1172/JCI129195. ISSN 0021-9738. Artikkelin verkkoversio.
F Ferrucci et al: The effects of amphetamine and methamphetamine on the release of norepinephrine, dopamine and acetylcholine from the brainstem reticular formation. Frontiers in Neuroanatomy, 2019, 13. vsk. PubMed:31133823. doi:10.3389/fnana.2019.00048. ISSN 1662-5129. Artikkelin verkkoversio.
DD Han, HH Gu: Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacology, 2006, 6. vsk, s. 6–13. PubMed:16515684. doi:10.1186/1471-2210-6-6. ISSN 1471-2210. Artikkelin verkkoversio.
PS Hasenhuetl et al: A kinetic account for amphetamine-induced monoamine release. The Journal of General Physiology, 2018, 150. vsk, nro 3, s. 431–451. PubMed:29439119. doi:10.1085/jgp.201711915. ISSN 0022-1295. Artikkelin verkkoversio.
FP Mayer et al: An unsuspected role for organic cation transporter 3 in the actions of amphetamine. Neuropsychopharmacology, 2018, 43. vsk, nro 12, s. 2408–2417. PubMed:29773909. doi:10.1038/s41386-018-0053-5. ISSN 0893-133X. Artikkelin verkkoversio.
Z Freyberg et al: Mechanisms of amphetamine action illuminated through optical monitoring of dopamine synaptic vesicles in Drosophila brain. Nature Communications, 2016, 7. vsk, nro 10652. PubMed:26879809. doi:10.1038/ncomms10652. ISSN 2041-1723. Artikkelin verkkoversio.
LD Simmler et al: In vitro characterization of psychoactive substances at rat, mouse, and human trace amine-associated receptor 1. Journal of Pharmacology and Experimental Therapeutics, 2016, 357. vsk, nro 1, s. 134–144. PubMed:26791601. doi:10.1124/jpet.115.229765. ISSN 0022-3565. Artikkelin verkkoversio.
J Liu, R Wu, J Li: TAAR1 and psychostimulant addiction. Cellular and Molecular Neurobiology, 2020, 40. vsk, nro 2, s. 229–238. PubMed:31974906. doi:10.1007/s10571-020-00792-8. ISSN 1573-6830. Artikkelin verkkoversio.
IH Ulus, TJ Maher, RJ Wurtman: Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors. Biochemical Pharmacology, 2000, 59. vsk, nro 12, s. 1611–1621. PubMed:10799660. doi:10.1016/s0006-2952(00)00306-3. ISSN 0006-2952. Artikkelin verkkoversio.
J Kitanaka, N Kitanaka, M Takemura: Modification of monoaminergic activity by MAO inhibitors influences methamphetamine actions. Drug Target Insights, 2006, 1. vsk, s. 19–28. PubMed:21901055. doi:10.1177/117739280600100001. ISSN 1177-3928. Artikkelin verkkoversio.
SE Hadland, S Levy: Objective testing - urine and other drug tests. Child and adolescent psychiatric clinics of North America, 2016, 25. vsk, nro 3, s. 549–565. PubMed:27338974. doi:10.1016/j.chc.2016.02.005. ISSN 1056-4993. Artikkelin verkkoversio.
L Edeleano: Ueber einige derivate der phenylmethacrylsäure und der phenylisobuttersäure. Berichte der deutschen chemischen Gesellschaft, 1887, 20. vsk, nro 1, s. 616–622. doi:10.1002/cber.188702001142. ISSN 1099-0682. Artikkelin verkkoversio.
BA Clement eta l: Toxic amines and alkaloids from Acacia berlandieri. Phytochemistry, 1997, 46. vsk, nro 2, s. 249–254. doi:10.1016/S0031-9422(97)00240-9. ISSN 0031-9422. Artikkelin verkkoversio.
SM Berman et al: Potential adverse effects of amphetamine treatment on brain and behavior: a review. Molecular Psychiatry, 2009, nro 2, s. 123–142. PubMed:18698321. doi:10.1038/mp.2008.90. ISSN 1476-5578. Artikkelin verkkoversio.
MP Strohl: Bradley’s benzedrine studies on children with behavioral disorders. The Yale Journal of Biology and Medicine, 2011, 84. vsk, nro 1, s. 27–33. PubMed:21451781. ISSN 0044-0086. Artikkelin verkkoversio.

yle.fi

Oopiumia yskänlääkkeeksi ja heroiinia kipuun – vielä ehdit nähdä, miten sodan vammoja lääkittiin yle.fi. Viitattu 30.9.2021.